Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23054117 | 0.92 | CYP2D6 (0.48) | CYP2D6LMNABLMTSHRKMT2A | |
| SCHEMBL4245452 | 0.92 | CHRM2 (0.48) | CYP2D6LMNABLMTSHRKMT2A | |
| SCHEMBL70308 | 0.92 | CHRM2 (0.48) | CYP2D6LMNABLMTSHRKMT2A | |
| Hydrochloric Acid SCHEMBL7738556 | 0.90 | CYP2D6 (0.46) | CYP2D6LMNABLMTSHRKMT2A | |
| SCHEMBL6513544 | 0.83 | CHRM2 (0.42) | CYP2D6LMNABLMTSHRKMT2A | |
| SCHEMBL6285170 | 0.83 | CHRM2 (0.42) | CYP2D6LMNABLMTSHRKMT2A | |
| SCHEMBL6285175 | 0.83 | CHRM2 (0.42) | CYP2D6LMNABLMTSHRKMT2A | |
| SCHEMBL18510082 | 0.82 | CYP2D6 (0.63) | CYP2D6LMNABLMTSHRKMT2A | |
| SCHEMBL107090 | 0.82 | CYP2D6 (0.63) | CYP2D6LMNABLMTSHRKMT2A | |
| SCHEMBL68389 | 0.82 | CYP2D6 (0.63) | CYP2D6LMNABLMTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | FEURER ACHIM | 2009-01-22 | — | — | US | disclosed |
| US-7427617-B2 | Morpoline-bridged indazole derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-23 | — | — | US | disclosed |
| US-20060128700-A1 | e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia | BAYER HEALTHCARE AG (DE) | 2006-06-15 | — | — | US | disclosed |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | OPRM1, OPRK1, OPRD1 | CYP2D6 649/4885LMNA 4050/4885BLM 3253/4885 |
| US-20060128700-A1 | e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia | GUCY1B2, COG4, GUCY1A2 | CYP2D6 4616/4885LMNA 4437/4885BLM 4058/4885 |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | GUCY1A1, PDE1A, PDE3B | CYP2D6 2737/4885LMNA 3343/4885BLM 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.